Who Should Buy this Cancer-Fighting Company

Oncology is one of the fastest growing segments of drug development and, given the needs of cancer suffers that aren't met, that's good news. It's also good business. Cancer-fighting drugs did an estimated $75 billion in global sales last year.

With that in mind, this episode of The Motley Fool's Market Checkup tackles the biggest news stories of the week involving cancer drugs, and the companies that make them. Watch and find out the latest on a potential biotech buyout, and which big pharma stock got a surprising result in late-stage trials.

In this video, health-care analysts David Williamson and Max Macaluso bring viewers up to date with the latest Onyx Pharmaceuticals vs. Amgen buyout drama, and whether some of the big pharmas sniffing around Onyx's cancer fighting drug portfolio would be a better strategic fit.

One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter: @MotleyDavid.

The article Who Should Buy this Cancer-Fighting Company originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.